Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023
Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) will participate in the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) will participate in the 41st Annual J.P. Morgan Health Care Conference from January 8-11, 2023, in San Francisco. The company will present at the Biotech Showcase on January 9 at 11:00am PST, focusing on its innovative development of intravenous-infused psilocin for high unmet medical needs. CEO Jim Gilligan and CBO Peter Molloy will also be available for investor meetings. Its lead program, TRP-8803, aims to enhance the therapeutic experience for patients with conditions like Binge Eating Disorder and fibromyalgia.
Details
News Market Reaction – TRYPF
The recorded move for TRYPF in the trading session of this news was -20.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to be in San Francisco January 8-11, 2023, during 41st Annual J.P. Morgan Health Care Conference
KELOWNA, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that the Company will be presenting at the Biotech Showcase on Monday, January 9, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.
Time: 11:00am PST
Track: Yosemite C (Ballroom Level)
Biotech Showcase is an investor conference featuring insights from top investors and biopharma executives.
Interested parties can register to attend the event here:
https://informaconnect.com/biotech-showcase/registration-options/
Additionally, CEO Jim Gilligan and CBO Peter Molloy will be in San Francisco from January 8-11, 2023, during the 41st Annual J.P. Morgan Health Care Conference and will be available for meetings with investors.
Individuals interested in meeting with CEO Jim Gilligan and CBO Peter Molloy can contact tryp@imsinvestorrelations.com.
About Tryp Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has an ongoing Phase 2a clinical trial for the treatment of Binge Eating Disorder at the University of Florida and an upcoming Phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit has been demonstrated, subsequent studies are expected to utilize TRP-8803 which has the potential to further improve efficacy, safety and patient experience. For more information, please visit www.tryptherapeutics.com.
Contact Information
John Nesbett/Jennifer Belodeau
IMS Investor Relations
51 Locust Avenue, New Canaan, CT
tryp@imsinvestorrelations.com
+1 203.972.9200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.